GMP, ISO custom synthesis Medicinal Chemistry; FDA new API and Intermediates, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided.
Teva, Novartis, Pfizer, Hikma, Glenmark, Gilead all Site Audit approved us.
www.eosmedchem.com
1.
Copanlisib HCL, CAS#1402152-13-9, HPLC 99.25%, HNMR, C13-NMR, LCMS, MSDS, COA, MOA all we provided. White powder, stock more than 100G.
Name: Copanlisib HCl
CAS#: 1402152-13-9 (HCl)
Chemical Formula: C23H30Cl2N8O4
Exact Mass:
Molecular Weight: 553.445
Elemental Analysis: C, 49.92; H, 5.46; Cl, 12.81; N, 20.25; O, 11.56
Synonym: Copanlisib HCl; Copanlisib dihydrochloride; BAY 80-6946; BAY80-6946; BAY-80-6946; BAY806946; BAY-806946; BAY 806946; Copanlisib; trade name Aliqopa.
IUPAC/Chemical Name: 5-Pyrimidinecarboxamide, 2-amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, hydrochloride (1:2)
InChi Key: STGQPVQAAFJJFX-UHFFFAOYSA-N
InChi Code: STGQPVQAAFJJFX-UHFFFAOYSA-N
SMILES Code: O=C(C1=CN=C(N)N=C1)NC2=NC3=C(C=CC(OCCCN4CCOCC4)=C3OC)C5=NCCN25.[H]Cl.[H]Cl
Appearance: Solid powder
Copanlisib free base, CAS#1032568-63-0, HPLC 99.2%, HNMR, C13-NMR, LCMS, MSDS, COA, MOA all we provided. White powder.
Name: Copanlisib free base
CAS#: 1032568-63-0 (free base)
Chemical Formula: C23H28N8O4
Exact Mass: 480.22335
Molecular Weight: 480.52
Elemental Analysis: C, 57.49; H, 5.87; N, 23.32; O, 13.32
Related CAS #: 1402152-13-9 (HCl) 1032568-63-0 (free base)
Synonym: BAY 80-6946; BAY80-6946; BAY-80-6946; BAY806946; BAY-806946; BAY 806946; Copanlisib free base
IUPAC/Chemical Name: 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide
InChi Key: PZBCKZWLPGJMAO-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)
SMILES Code: O=C(C1=CN=C(N)N=C1)NC2=NC3=C(C=CC(OCCCN4CCOCC4)=C3OC)C5=NCCN25.
2.
Copanlisib Intermediates:
Copanlisib IntermediateN-1, CAS#:1032570-74-3, HPLC 99%, HNMR, LCMS, MSDS, COA, MOA all we provided, More than 100G in stock.
Copanlisib IntermediateN-1, 2-amino-3-methoxy-4-(3-morpholin-4-ylpropoxy)benzonitrile, CAS#:1032570-98-1, HPLC 99%, HNMR, LCMS, MSDS, COA, MOA all we provided, More than 1KG in stock.
Copanlisib IntermediateN-2, 5-amino-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-8-ol, CAS#:1032570-76-5, HPLC 99%, HNMR, LCMS, MSDS, COA, MOA all we provided, More than 10KG in stock.
Copanlisib IntermediateN-3, 8-(benzyloxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine, CAS#:1032570-69-6, HPLC 99%, HNMR, LCMS, MSDS, COA, MOA all we provided, More than 10KG in stock.
Copanlisib IntermediateN-4, 3-(benzyloxy)-6-(4,5-dihydro-1H-imidazol-2-yl)-2-methoxyaniline, CAS#:887202-50-8, HPLC 99%, HNMR, LCMS, MSDS, COA, MOA all we provided, More than 10KG in stock.
Copanlisib IntermediateN-5, 2-amino-4-(benzyloxy)-3-methoxybenzonitrile, CAS#: 1032570-65-2, HPLC 99%, HNMR, LCMS, MSDS, COA, MOA all we provided, More than 1KG in stock.
Copanlisib IntermediateN-6, 4-(benzyloxy)-3-methoxy-2-nitrobenzonitrile, CAS#: 1019115-11-7, HPLC 99%, HNMR, LCMS, MSDS, COA, MOA all we provided, More than 1KG in stock.
3.
Raw materials:
| 3167-50-8 | 2-Aminopyrimidine-5-carboxylic acid |
| 7357-67-7 | N-(3-Chloropropyl)morpholine |
| 107-15-3 | Ethylenediamine |
| 2450-26-2 | 4-Hydroxy-3-Methoxy-2-nitro-benzaldehyde |
| 2698-69-3 | 4-formyl-2-methoxy-3-nitrophenyl acetate |
| 881-68-5 | Vanillin acetate |
| 2450-27-3 | 4-(benzyloxy)-3-Methoxy-2-nitrobenzaldehyde |
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
2018. 4.18 Janpan CPHI, Attend
2018. 5.15 Israel Biomed, Attend
2018. 6. 20 China CPHI, W4E82
2018. 8. 28 Korea CPHI, Attend
2018. 10. 9 Spain World CPHI, Attend
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
REFERENCES
1: Milewska M, Cremona M, Morgan C, O'Shea J, Carr A, Velanki SH, Hopkins AM, Toomey S, Madden SF, Hennessy BT, Eustace AJ. Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. Ther Adv Med Oncol. 2018 Jan 9;10:1758834017746040. doi: 10.1177/1758834017746040. eCollection 2018. PubMed PMID: 29383036; PubMed Central PMCID: PMC5784557.
2: Kim RD, Alberts SR, Peña C, Genvresse I, Ajavon-Hartmann A, Xia C, Kelly A, Grilley-Olson JE. Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. Br J Cancer. 2018 Feb 20;118(4):462-470. doi: 10.1038/bjc.2017.428. Epub 2018 Jan 18. PubMed PMID: 29348486.
3: Thieblemont C. Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):371-378. doi: 10.1182/asheducation-2017.1.371. Review. PubMed PMID: 29222281.
4: Simpson I. An industry update: the latest developments in therapeutic delivery. Ther Deliv. 2018 Jan;9(1):9-15. doi: 10.4155/tde-2017-0109. PubMed PMID: 29216806.
5: Greenwell IB, Ip A, Cohen JB. PI3K Inhibitors: Understanding Toxicity Mechanisms and Management. Oncology (Williston Park). 2017 Nov 15;31(11):821-8. Review. PubMed PMID: 29179250.
6: O'Shea J, Cremona M, Morgan C, Milewska M, Holmes F, Espina V, Liotta L, O'Shaughnessy J, Toomey S, Madden SF, Carr A, Elster N, Hennessy BT, Eustace AJ. A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. Oncotarget. 2017 Jul 22;8(49):85120-85135. doi: 10.18632/oncotarget.19461. eCollection 2017 Oct 17. PubMed PMID: 29156708; PubMed Central PMCID: PMC5689598.
7: Markham A. Copanlisib: First Global Approval. Drugs. 2017 Dec;77(18):2057-2062. doi: 10.1007/s40265-017-0838-6. PubMed PMID: 29127587.
8: Argnani L, Broccoli A, Zinzani PL. Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. Cancer Treat Rev. 2017 Dec;61:61-69. doi: 10.1016/j.ctrv.2017.10.007. Epub 2017 Oct 28. Review. PubMed PMID: 29102679.
9: Copanlisib Produces Prolonged Responses in Lymphoma. Cancer Discov. 2017 Dec;7(12):OF2. doi: 10.1158/2159-8290.CD-NB2017-147. Epub 2017 Oct 25. PubMed PMID: 29070613.
10: Das M. Copanlisib in heavily pretreated indolent lymphoma. Lancet Oncol. 2017 Nov;18(11):e650. doi: 10.1016/S1470-2045(17)30783-0. Epub 2017 Oct 13. PubMed PMID: 29033198.
11: Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4. PubMed PMID: 28976790.
12: Broccoli A, Argnani L, Zinzani PL. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. Cancer Treat Rev. 2017 Nov;60:120-129. doi: 10.1016/j.ctrv.2017.09.002. Epub 2017 Sep 18. Review. PubMed PMID: 28946015.
13: Lampson BL, Brown JR. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs. 2017 Nov;26(11):1267-1279. doi: 10.1080/13543784.2017.1384815. Epub 2017 Oct 6. Review. PubMed PMID: 28945111; PubMed Central PMCID: PMC5747968.
14: Robak P, Robak T. Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017 Nov;26(11):1249-1265. doi: 10.1080/13543784.2017.1384814. Epub 2017 Oct 3. Review. PubMed PMID: 28942659.
15: Gerisch M, Schwarz T, Lang D, Rohde G, Reif S, Genvresse I, Reschke S, van der Mey D, Granvil C. Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [(14)C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers. Cancer Chemother Pharmacol. 2017 Sep;80(3):535-544. doi: 10.1007/s00280-017-3383-9. Epub 2017 Jul 11. PubMed PMID: 28714036; PubMed Central PMCID: PMC5573760.
16: Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, Hiemeyer F, Giurescu M, Garcia-Vargas J, Gorbatchevsky I, Liu L, Koechert K, Peña C, Neves M, Childs BH, Zinzani PL. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017 Sep 1;28(9):2169-2178. doi: 10.1093/annonc/mdx289. PubMed PMID: 28633365.
17: Lim SY, Menzies AM, Rizos H. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer. 2017 Jun 1;123(S11):2118-2129. doi: 10.1002/cncr.30435. Review. PubMed PMID: 28543695.
18: Zinzani PL, Broccoli A. Possible novel agents in marginal zone lymphoma. Best Pract Res Clin Haematol. 2017 Mar - Jun;30(1-2):149-157. doi: 10.1016/j.beha.2016.07.003. Epub 2016 Nov 4. Review. PubMed PMID: 28288710.
19: Paul J, Soujon M, Wengner AM, Zitzmann-Kolbe S, Sturz A, Haike K, Keng Magdalene KH, Tan SH, Lange M, Tan SY, Mumberg D, Lim ST, Ziegelbauer K, Liu N. Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT. Cancer Cell. 2017 Jan 9;31(1):64-78. doi: 10.1016/j.ccell.2016.12.003. PubMed PMID: 28073005.
